Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Breast cancer patients often have sleep disturbances during the perioperative period.
Dexmedetomidine is a highly selective alpha 2-adrenoceptor agonist with sedative, anxiolytic,
and analgesic effects. Previous studies showed that night-time low-dose dexmedetomidine
infusion improved sleep quality. Esketamine is a N-methyl-D-aspartic acid receptor antagonist
and has been used as an anesthetic and analgesic. Recent studies showed that low-dose
esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that
low-dose dexmedetomidine-esketamine combined nasal administration at night can improve
perioperative sleep quality in patients scheduled for breast cancer surgery.